DaniellePeterselMD

Rheumatology • Syosset, NY

Systemic Pain & Inflammatory Syndromes

Rheumatology, Syosset NY Medical Director, Pfizer

Join to view full profile

Dr. Petersel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Petersel's full profile

Already have an account?

Office
5 Wood Court
Syosset, NY 11791
Phone+1 646-734-9431

Education & Training

Rutgers Robert Wood Johnson Medical SchoolFellowship, Rheumatology, 2004 - 2006
Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalResidency, Internal Medicine, 2001 - 2004
SUNY Upstate Medical UniversityClass of 2001
Cornell UniversityB.S., 1996

Certifications & Licensure

NY State Medical License 2004 - 2025
NJ State Medical License 2005 - 2009
AHIMIntegrative and Holistic Medicne

Awards, Honors, & Recognition

Certificate in Excellence in Teaching UMDNJ-RWJMS, 2005
Fellow American College of Rheumatology

Clinical Trials

A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy Start of enrollment: 2005 May 01
Completed
Phase 3
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA) Start of enrollment: 2008 May 01
Completed
Phase 3
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2009 Oct 31
Completed
Phase 3
Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation Start of enrollment: 2009 Oct 01
Completed
Phase 4
A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis Start of enrollment: 2010 Oct 01
Completed
Phase 3
Study of the Response and Cardiorespiratory Endurance in Early RA Patients Treated With Tocilizumab or Methotrexate Start of enrollment: 2010 May 01
Completed
Not Applicable
Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients Start of enrollment: 2010 Dec 01
Completed
Phase 3
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF Start of enrollment: 2011 Nov 30
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

23 citations
Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Robert J. Moots, Cinzia Curiale, Danielle Petersel, Catherine Rolland, Heather Jones
Biodrugs. 2018-05-22
39 citations
Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.
José Manuel Carrascosa, Ira Jacobs, Danielle Petersel, Robert Strohal
Dermatology and Therapy. 2018-03-16
77 citations
The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects
Paul Declerck, Romano Danesi, Danielle Petersel, Ira Jacobs
Drugs. 2017-04-01

Journal Articles

Venous thromobembolism prophylaxis and clinical consequences in medically ill patients
Baser O, Liu X, Phatak H, Wang L, Mardekian J, Kawabata H, Petersel D, Hamilton M, Ramacciotti E, Am J Ther, 3/1/2013
Survey of physician experiences and perceptions about the diagnosis and treatment of fibromyalgia
Perrot S, Choy E, Petersel D, Ginovker A, Kramer E, BMC Health Serv Res, 10/10/2012
Long-term maintenance of response across multiple fibromyalgia symptom domains in a randomized withdrawal study of pregabalin
Pauer L, Atkinson G, Murphy TK, Petersel D, Zeiher B, Clin J Pain, 9/1/2012
Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 open-label extension studies in patients with fibromyalgia
Arnold LM, Emir B, Murphy TK, Zeiher BG, Paure L, Scott G, Petersel D, Clin Ther, 5/1/2012
FibroCollaborative A framework for fibromyalgia management for primary care providers
Arnold LM, Clauw DJ, Dunegan LJ, Turk DC, Mayo Clin Proc, 5/1/2012
FibroCollaborative Improving the recognition and diagnosis of fibromyalgia
Arnold LM, Clauw DJ, McCarberg BH, Mayo Clin Proc, 5/1/2011
Central amplification and fibromyalgia: disorder of pain processing
Petersel DL, Dror V, Cheung R, J Neurosci Res, 1/1/2011
Pregabalin in treatment-refractory fibromyalgia
Stacey BR, Emir B, Petersel D, Murphy K, Open Rheumatol J, 10/1/2010
Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics
Emir B, Murphy TK, Petersel DL, Whalen E, Expert Opin Pharmacother, 1/1/2010
Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials
Bhadra P, Petersel D, Expert Opin Pharmacother, 1/1/2010
A patient survey of the impact of fibromyalgia and the journey to diagnosis
Choy E, Perrot S, Leon T, Kaplan J, Petersel D, Ginovker A, Kramer E, BMC Health Serv Res, 1/1/2010
Treatment of Acute Gout in Hospitalized Patients
Petersel D, Schlesinger N, J Rheumatol, 7/1/2007
Reactive Arthritis: A review
Petersel D, Schlesinger N, Infectious Disease Clinics of North America, 12/1/2005
Join now to see all